Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DSS, INC.DSS · Entity 8811 | Chief Operating Officer | July 23, 2019 | July 24, 2019 |
| IMPACT BIOMEDICAL INC.IBO · Entity 7209 | Director | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DSS, INC.
Report date July 23, 2019 · Filed July 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,770 |
Reported balance
After 2019-07-23 transaction · row 1
1 source rowRow 1 · 2019-07-23 · Grant · Acquired 74,770 · Balance 74,770 F1: Represents a restricted stock grant awarded to the Reporting Person by the Issuer pursuant to the Company's 2013 Employee, Director and Consultants Equity Incentive Plan in consideration for the Reporting Person's services as Chief Operating Officer of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock grant awarded to the Reporting Person by the Issuer pursuant to the Company's 2013 Employee, Director and Consultants Equity Incentive Plan in consideration for the Reporting Person's services as Chief Operating Officer of the Issuer.
IMPACT BIOMEDICAL INC.
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,182 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Sale · Disposed 50,000 · Balance 250,182 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 25, 2026 19:55 UTC | IMPACT BIOMEDICAL INC. IBO · Entity 7209 | SaleCommon Stock | 50,000 | $0.65 | $32,505.00 |
DisclosureSEC source: 0001493152-26-012746 · ownership.xml · nonDerivative · entry 1 Grady Jason · CIK 0001782482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,182 Read SEC document |
| July 23, 2019 Filed Jul 24, 2019 22:13 UTC | DSS, INC. DSS · Entity 8811 | GrantCommon Stock | 74,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-011061 · ownership.xml · nonDerivative · entry 1 Grady Jason · CIK 0001782482 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,770 F1 · shares: Represents a restricted stock grant awarded to the Reporting Person by the Issuer pursuant to the Company's 2013 Employee, Director and Consultants Equity Incentive Plan in consideration for the Reporting Person's services as Chief Operating Officer of the Issuer. F1 · price: Represents a restricted stock grant awarded to the Reporting Person by the Issuer pursuant to the Company's 2013 Employee, Director and Consultants Equity Incentive Plan in consideration for the Reporting Person's services as Chief Operating Officer of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.